Compare HDRN & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HDRN | XTNT |
|---|---|---|
| Founded | 2024 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.2M | 39.6M |
| IPO Year | 2024 | 2009 |
| Metric | HDRN | XTNT |
|---|---|---|
| Price | $0.58 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.03 |
| AVG Volume (30 Days) | 142.1K | ★ 147.0K |
| Earning Date | 11-09-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $53,337,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $0.27 |
| 52 Week High | $2.67 | $0.84 |
| Indicator | HDRN | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 28.97 | 35.92 |
| Support Level | N/A | N/A |
| Resistance Level | $0.94 | $0.33 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 3.34 | 9.29 |
Hadron Energy Inc is a nuclear technology company focused on developing factory-fabricated, transportable 10 megawatt-electric (MWe) micro-modular reactors (MMRs) to meet the growing demand for clean, reliable, and affordable power. The company aims to deliver scalable, carbon-free energy solutions that can be rapidly deployed to power a variety of industries, including data centers, industrial facilities, remote communities, government installations and more. The market segments for its proprietary reactor, Hadron Halos, are Data Centers, Industrial Facilities and Heavy Manufacturing, Remote Communities and Critical Infrastructure, and Utilities and Distributed Energy.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.